A ranar 19 ga Mayu, 2022, Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) ta amince da aikace-aikacen tallata na Bayer's.Vericiguat(2.5 MG, 5 MG, da 10 MG) a ƙarƙashin sunan alamar Verquvo™.

Ana amfani da wannan miyagun ƙwayoyi a cikin tsofaffi marasa lafiya tare da alamun cututtuka na ciwon zuciya na zuciya da kuma rage raguwar ejection (ɓangarorin fitarwa <45%) waɗanda aka tabbatar da su bayan wani abin da ya faru a kwanan nan tare da maganin jijiya, don rage haɗarin asibiti don ciwon zuciya ko gaggawa na gaggawa na diuretic.

Amincewa da Vericiguat ya dogara ne akan sakamako mai kyau daga binciken VICTORIA, wanda ya nuna cewa Vericiguat na iya kara rage yawan haɗarin mutuwar zuciya da kuma asibiti don ciwon zuciya ta hanyar 4.2% (cikakken hadarin raguwa / 100 haƙuri-shekaru) ga marasa lafiya da zuciya. gazawar wanda ya sami raunin raunin zuciya na kwanan nan kuma sun kasance masu tsayayye akan jiyya na jijiya tare da rage juzu'in fitarwa (rashin fitarwa <45%).

A cikin Janairu 2021, an amince da Vericiguat a cikin Amurka don maganin cututtukan cututtukan zuciya na yau da kullun a cikin marasa lafiya tare da juzu'in fitar da ƙasa da kashi 45% bayan fuskantar matsalar gazawar zuciya.

A cikin watan Agusta 2021, sabuwar aikace-aikacen magani na Vericiguat ta karɓi ta CDE kuma daga baya an haɗa ta cikin fifikon bita da tsarin amincewa bisa dalilan "magungunan gaggawa na asibiti, sabbin magunguna da ingantattun sabbin magunguna don rigakafi da maganin manyan cututtuka cututtuka masu wuya”.

A cikin Afrilu 2022, Jagoran AHA/ACC/HFSA na 2022 don Gudanar da Rashin Ciwon Zuciya, wanda Cibiyar Nazarin Zuciya ta Amurka (ACC), Ƙungiyar Zuciya ta Amurka (AHA), da Ƙungiyar Ciwon Zuciya ta Amurka (HFSA) suka bayar tare. ), sabunta maganin magunguna na rashin ciwon zuciya tare da raguwar raguwar fitarwa (HFrEF) kuma sun haɗa da Vericiguat a cikin magungunan da ake amfani da su don kula da marasa lafiya masu haɗari. HFrEF da haɓakar gazawar zuciya dangane da daidaitaccen jiyya.

VericiguatsGC (mai narkewa guanylate cyclase) mai motsa kuzari tare da tsarin novel wanda Bayer da Merck Sharp & Dohme (MSD) suka haɓaka tare. Yana iya shiga tsakani kai tsaye a cikin rashin aikin siginar salula da gyara hanyar NO-sGC-cGMP.

Nazarce-nazarce da na asibiti sun nuna cewa NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) hanyar siginar siginar ita ce manufa mai yuwuwar ci gaban cututtukan zuciya na zuciya da bugun zuciya. A ƙarƙashin yanayin ilimin lissafin jiki, wannan hanyar sigina ita ce hanya mai mahimmanci don sarrafa makanikai na zuciya, aikin zuciya, da aikin endothelial na jijiyoyin jini.

A ƙarƙashin yanayin pathophysiological na gazawar zuciya, ƙãra ƙumburi da rashin aiki na jijiyoyi suna rage NO bioavailability da ƙananan cGMP kira. Rashin rashi na cGMP yana haifar da dysregulation na tashin hankali na jijiyoyin jini, jijiyoyin bugun jini da sclerosis, fibrosis da hypertrophy, da ciwon zuciya da na koda microcirculatory tabarbarewa, don haka ya kara haifar da ci gaba da ciwon zuciya, ƙara yawan kumburi da kuma kara raguwa a cikin aikin zuciya da na koda.